Non-cystic fibrosis bronchiectasis

Simon Finch, Alison Dicker, James Chalmers (Lead / Corresponding author)

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

Abstract

Exacerbations of bronchiectasis are common, with European data suggesting that the average patient experiences two exacerbations per year. Exacerbations have been associated with worse QoL, lung function decline and increased mortality. Exacerbations are highly heterogeneous, presenting most frequently with increasing cough and sputum production, but also commonly with breathlessness, wheeze, malaise and systemic features. There is a lack of research into the causes of bronchiectasis exacerbations, but antibiotic therapy is currently recommended for all exacerbations because of the high frequency of bacterial infection in the disease. Exacerbations are the primary end-point for the majority of late-phase bronchiectasis clinical trials, although these have been limited by the lack of a standardised definition. The EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) network, in collaboration with colleagues from the USA, Australasia and South Africa, has recently generated a consensus definition of exacerbations, which should help to standardise outcomes. Exacerbations are key events in the natural history of bronchiectasis. There is an urgent need for further research into the causes, optimal management and outcomes of bronchiectasis exacerbations.
Original languageEnglish
Title of host publicationAcute Exacerbations of Pulmonary Diseases
EditorsPierre-Régis Burgel, Marco Contoli, José Luis López-Campos
PublisherEuropean Respiratory Society
Chapter4
Pages38-57
Number of pages20
ISBN (Electronic)9781849840903
DOIs
Publication statusPublished - 1 Sep 2017

Fingerprint

Bronchiectasis
Fibrosis
Research
Australasia
South Africa
Sputum
Bacterial Infections
Cough
Dyspnea
Clinical Trials
Anti-Bacterial Agents
Lung
Mortality

Cite this

Finch, S., Dicker, A., & Chalmers, J. (2017). Non-cystic fibrosis bronchiectasis. In P-R. Burgel, M. Contoli, & J. L. López-Campos (Eds.), Acute Exacerbations of Pulmonary Diseases (pp. 38-57). European Respiratory Society. https://doi.org/10.1183/2312508X.10015816
Finch, Simon ; Dicker, Alison ; Chalmers, James. / Non-cystic fibrosis bronchiectasis. Acute Exacerbations of Pulmonary Diseases. editor / Pierre-Régis Burgel ; Marco Contoli ; José Luis López-Campos. European Respiratory Society, 2017. pp. 38-57
@inbook{29adeb970846478b91eda646f0ff9bca,
title = "Non-cystic fibrosis bronchiectasis",
abstract = "Exacerbations of bronchiectasis are common, with European data suggesting that the average patient experiences two exacerbations per year. Exacerbations have been associated with worse QoL, lung function decline and increased mortality. Exacerbations are highly heterogeneous, presenting most frequently with increasing cough and sputum production, but also commonly with breathlessness, wheeze, malaise and systemic features. There is a lack of research into the causes of bronchiectasis exacerbations, but antibiotic therapy is currently recommended for all exacerbations because of the high frequency of bacterial infection in the disease. Exacerbations are the primary end-point for the majority of late-phase bronchiectasis clinical trials, although these have been limited by the lack of a standardised definition. The EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) network, in collaboration with colleagues from the USA, Australasia and South Africa, has recently generated a consensus definition of exacerbations, which should help to standardise outcomes. Exacerbations are key events in the natural history of bronchiectasis. There is an urgent need for further research into the causes, optimal management and outcomes of bronchiectasis exacerbations.",
author = "Simon Finch and Alison Dicker and James Chalmers",
year = "2017",
month = "9",
day = "1",
doi = "10.1183/2312508X.10015816",
language = "English",
pages = "38--57",
editor = "Pierre-R{\'e}gis Burgel and Marco Contoli and L{\'o}pez-Campos, {Jos{\'e} Luis}",
booktitle = "Acute Exacerbations of Pulmonary Diseases",
publisher = "European Respiratory Society",

}

Finch, S, Dicker, A & Chalmers, J 2017, Non-cystic fibrosis bronchiectasis. in P-R Burgel, M Contoli & JL López-Campos (eds), Acute Exacerbations of Pulmonary Diseases. European Respiratory Society, pp. 38-57. https://doi.org/10.1183/2312508X.10015816

Non-cystic fibrosis bronchiectasis. / Finch, Simon; Dicker, Alison; Chalmers, James (Lead / Corresponding author).

Acute Exacerbations of Pulmonary Diseases. ed. / Pierre-Régis Burgel; Marco Contoli; José Luis López-Campos. European Respiratory Society, 2017. p. 38-57.

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

TY - CHAP

T1 - Non-cystic fibrosis bronchiectasis

AU - Finch, Simon

AU - Dicker, Alison

AU - Chalmers, James

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Exacerbations of bronchiectasis are common, with European data suggesting that the average patient experiences two exacerbations per year. Exacerbations have been associated with worse QoL, lung function decline and increased mortality. Exacerbations are highly heterogeneous, presenting most frequently with increasing cough and sputum production, but also commonly with breathlessness, wheeze, malaise and systemic features. There is a lack of research into the causes of bronchiectasis exacerbations, but antibiotic therapy is currently recommended for all exacerbations because of the high frequency of bacterial infection in the disease. Exacerbations are the primary end-point for the majority of late-phase bronchiectasis clinical trials, although these have been limited by the lack of a standardised definition. The EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) network, in collaboration with colleagues from the USA, Australasia and South Africa, has recently generated a consensus definition of exacerbations, which should help to standardise outcomes. Exacerbations are key events in the natural history of bronchiectasis. There is an urgent need for further research into the causes, optimal management and outcomes of bronchiectasis exacerbations.

AB - Exacerbations of bronchiectasis are common, with European data suggesting that the average patient experiences two exacerbations per year. Exacerbations have been associated with worse QoL, lung function decline and increased mortality. Exacerbations are highly heterogeneous, presenting most frequently with increasing cough and sputum production, but also commonly with breathlessness, wheeze, malaise and systemic features. There is a lack of research into the causes of bronchiectasis exacerbations, but antibiotic therapy is currently recommended for all exacerbations because of the high frequency of bacterial infection in the disease. Exacerbations are the primary end-point for the majority of late-phase bronchiectasis clinical trials, although these have been limited by the lack of a standardised definition. The EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) network, in collaboration with colleagues from the USA, Australasia and South Africa, has recently generated a consensus definition of exacerbations, which should help to standardise outcomes. Exacerbations are key events in the natural history of bronchiectasis. There is an urgent need for further research into the causes, optimal management and outcomes of bronchiectasis exacerbations.

U2 - 10.1183/2312508X.10015816

DO - 10.1183/2312508X.10015816

M3 - Chapter (peer-reviewed)

SP - 38

EP - 57

BT - Acute Exacerbations of Pulmonary Diseases

A2 - Burgel, Pierre-Régis

A2 - Contoli, Marco

A2 - López-Campos, José Luis

PB - European Respiratory Society

ER -

Finch S, Dicker A, Chalmers J. Non-cystic fibrosis bronchiectasis. In Burgel P-R, Contoli M, López-Campos JL, editors, Acute Exacerbations of Pulmonary Diseases. European Respiratory Society. 2017. p. 38-57 https://doi.org/10.1183/2312508X.10015816